Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings
Executive Summary
Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations
You may also be interested in...
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials